Podcasts about biomarkers

Moderator: Raffaele Dubbioso (Naples, Italy) Guest: Andrea Malaspina (London, UK) and Francesco Di Lorenzo (Rome, Italy) In this episode, Raffaele Dubbioso speaks with Andrea Malaspina and Francesco Di Lorenzo about the growing role of neurofilaments as biomarkers in amyotrophic lateral sclerosis and frontotemporal dementia. They discuss the biological basis and clinical interpretation of neurofilament measurements, their diagnostic and prognostic value, and their emerging role in identifying pre-symptomatic disease, monitoring progression, and supporting clinical trials in neurological practice.

What matters most to patients with non-muscle invasive bladder cancer (NMIBC)? In this episode of BackTable Urology, Dr. Kelly Bree, Dr. Saum Ghodoussipour, and Meredith Donahue, N.P., join host Dr. Vignesh Packiam to discuss the power of shared decision-making across the NMIBC spectrum. They explore risk-adapted treatment selection, when to escalate or de-escalate therapy, and how to navigate conversations about recurrence risk, treatment burden, quality of life, and the possibility of cystectomy. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by an educational grant from Johnson & Johnson. --- Timestamps 00:00 - Introduction01:55 - Second Opinions and Patient Counseling06:08 - Intermediate Risk Stratification12:13 - Treatment Options for Intermediate Risk NMIBC16:20 - BCG and Alternative Treatments for High Risk NMIBC26:49 - Options for BCG-Unresponsive NMIBC31:42 - Sequencing and Cystectomy37:03 - Financial and Time Toxicity41:08 - Biomarkers and ctDNA44:04 - Future Trials and NMIBC Innovations --- More about this episode They also review emerging therapies such as ZUSDURI, the evolving role of intravesical treatments, and the promise of biomarkers and ctDNA for personalized care. The discussion covers practical strategies for patient counseling, key updates to clinical guidelines, and a preview of innovations shaping the future of NMIBC management. --- Resources Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial:https://pubmed.ncbi.nlm.nih.gov/41571573/ Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non–Muscle-Invasive Bladder Cancerhttps://ascopubs.org/doi/10.1200/JCO-25-01324 CIRCULATING TUMOR DNA AS A BIOMARKER FOR UPSTAGING AND ADVERSE PATHOLOGY IN HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER:https://www.auajournals.org/doi/abs/10.1097/01.JU.0001191388.74345.c9.09 Preoperative Circulating Tumor DNA Predicts Upstaging and Recurrence in High-Risk Nonmuscle-Invasive Bladder Cancer Undergoing Radical Cystectomyhttps://pubmed.ncbi.nlm.nih.gov/41843048/ --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

Why do two people with Parkinson's experience the disease so differently?In this episode, we sit down with researchers Patrik Verstreken and Natalie Kaempf to explore groundbreaking work that may help answer that question. Using advanced biology, biomarkers, and artificial intelligence, their team has identified what could be five distinct biological subtypes of Parkinson's disease.We discuss what these findings mean for people living with Parkinson's today, how genetics and environmental factors may influence disease progression, and why understanding the biology behind Parkinson's could lead to more personalized treatments, better clinical trials, and earlier diagnosis in the future.Chapters00:00 Introduction to Parkinson's Disease Research02:54 Understanding the Variability of Parkinson's Disease06:07 Symptomatic Treatments vs. Underlying Causes08:57 Subtypes of Parkinson's Disease11:51 The Role of Biomarkers in Early Diagnosis14:46 AI's Impact on Parkinson's Research18:10 Clinical Trials and Treatment Stratification20:59 Future Directions in Parkinson's Disease Treatment23:55 The Importance of Community and Hope

Are medical advancements closing or widening medical disparities? Eugene Manley, Jr., Ph.D., founder and CEO of the STEMM & Cancer Health Equity Foundation, breaks down why equity is still not completely measurable in clinical trials, what proper representation in studies is, and how certain demographics are at a disadvantage for biomarker tests compared to other groups with host Deborah Borfitz. Their conversation explores whether health equity in cancer trials is different compared to commonly occurring diseases and if basket and umbrella trials may help the move the needle. Plus, the latest news on a pioneering phage therapy service, a unique cardiac arrest pilot study, new primary endpoints for cancer trials, and trial disruptions threatening diversity. Listen and let us know in a review: where do you think our time and resources are most needed for equity? Show Notes News Roundup Compassionate use phage therapy Article in Nature Medicine Press release from Monash University   Sudden cardiac death research  Study in Prehospital Emergency Care News on the University of Cincinnati website New endpoints for cancer trials Consensus paper in The Lancet Oncology News on the Medical University of Vienna website USC and Tempus strategic collaboration News on the Keck School of Medicine of USC website Trial disruptions threaten diversity Article in the Journal of Medical Internet Research Misinterpreting effects of Alzheimer's drugs Research letter in JAMA Neurology News from Brown University School of Public Health  Guest Eugene Manley, Jr., Ph.D., founder and CEO of the STEMM & Cancer Health Equity Foundation The Scope of Things podcast explores clinical research and its possibilities, promise, and pitfalls. Clinical Research News senior writer, Deborah Borfitz, welcomes guests who are visionaries closest to the topics, but who can still see past their piece of the puzzle. Focusing on game-changing trends and out-of-the-box operational approaches in the clinical research field, the Scope of Things podcast is your no-nonsense, insider's look at clinical research today.  

Depression is often treated as a single condition. But two people with the same diagnosis can have completely different underlying causes. On this episode of The Dr. Hyman Show, I'm rejoined by Dr. James Greenblatt to explore why depression may be less of a disease and more of a signal that something deeper is going on. We discuss how a root-cause approach can uncover what's driving symptoms and why finding what's beneath them matters. Watch the full conversation on YouTube or listen wherever you get your podcasts. We discuss: Could nutrient deficiencies, inflammation, or gut issues be contributing to symptoms of depression What tests can help uncover the biological factors that may be affecting mood and mental health Why can two people with depression have different root causes—and require different solutions How do blood sugar imbalances, hormone changes, and metabolic health influence the brain What should you know about antidepressants, tapering, and addressing the factors that may affect recovery Hope doesn't come from ignoring symptoms—it comes from understanding them. Sometimes the most important question isn't "What's wrong with me?" but "What might my body be trying to tell me?" One of the key themes in this conversation is that mental health is deeply connected to what's happening throughout the body. In my Brainshaping Academy, you'll learn how to support the biological systems that shape cognitive, emotional, and mental well-being. View Show Notes From This Episode Depression symptoms aren't always just “in your head.” Dr. Hyman's Brainshaping Academy shows how your gut, immune system, and nutrient levels may be responsible—and what you can do about it. → https://drhyman.com/products/brainshaping?utm_source=dr_hyman_show&utm_medium=newsletter&utm_campaign=may_27&utm_content=link Get Free Weekly Health Tips from Dr. Hyman https://drhyman.com/pages/picks?utm_campaign=shownotes&utm_medium=banner&utm_source=podcast Sign Up for Dr. Hyman's Weekly Longevity Journal https://drhyman.com/pages/longevity?utm_campaign=shownotes&utm_medium=banner&utm_source=podcast Join the 10-Day Detox to Reset Your Health https://drhyman.com/pages/10-day-detox Join the Hyman Hive for Expert Support and Real Results https://drhyman.com/pages/hyman-hive This episode is brought to you by Seed, Made In Cookware, Perfect Amino, BON CHARGE, and Big Bold Health.Go to seed.com/hyman and use code 20HYMAN to get 20% off your first month.Visit madeincookware.com and use code HYMAN10 for 10% off your order.Go to bodyhealth.com and use code HYMAN20 to get 20% off your first order.Head to boncharge.com/hyman and use code HYMAN for 15% off.Go to bigboldhealth.com/drhyman and use code HYMAN15 to save 15% on your first order. (0:00) Antidepressants, Cooking at Home, and Introducing the Brain Shaping Academy (3:14) Prevalence of Depression and Personal Stories (4:27) Exploring Root Causes of Depression (5:07) Influential Figures and Orthomolecular Psychiatry (12:29) Gut Health, Gluten Sensitivity, and Brain Inflammation (20:22) Neuroinflammation and Root Causes of Depression (22:10) Biomarkers, Hormonal Imbalances, and Insulin Resistance (25:34) The Role of Toxins and Diagnostic Testing (31:15) Case Studies and Patient Stories (34:29) Challenges in the Mental Health System (37:05) Effectiveness of Antidepressants and Patient Resistance (43:17) Role and Need for Nutritional Lithium (45:00) Sponsor: Big Bold Health (46:00) Identifying Nutritional Lithium Need (47:13) Integrating Modalities and Supplements vs. Medications (48:04) Psychotherapy Methods and Addressing Root Causes (49:34) Dr. Greenblatt's Book and the Finding a Living Platform (51:03) Systematic Approach and Global Impact of Depression (52:39) Sharing, Disclaimer, and Closing Remarks

Ready to move beyond “one-size-fits-all” for BCG-unresponsive NMIBC? In this episode of BackTable Urology, Dr. Ruchika Talwar hosts Dr. Sam Chang to discuss the evolving treatment landscape for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). They explore why BCG may fail, the science and clinical rationale behind new immunotherapies and gene therapies, practical approaches to patient selection, treatment sequencing, and surveillance, and the value of emerging biomarkers, empowering urologists to make more informed, personalized decisions in complex cases of NMIBC. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by ImmunityBiohttps://anktiva.com/ --- Timestamps 00:00 - Introduction03:48 - BCG: How it Works and Why it Fails11:13 - Pembrolizumab Role and Limits14:38 - Nadofaragene firadenovec 16:34 - Cretostimogene grenadenorepvec18:39 - BCG + Anktiva Rationale29:50 - Explaining Options to Patients33:05 - Post Treatment Surveillance37:32 - Future of Biomarkers and AI42:05 - Key Takeaways --- Resources N-803 Plus BCG Treatment for BCG-Naïve or -Unresponsive Non-Muscle Invasive Bladder Cancer: A Plain Language Reviewhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11524197/ Safety, Tolerability, and Long-Term Clinical Outcomes of an IL-15 analogue (N-803) Admixed with Bacillus Calmette-Guérin (BCG) for the Treatment of Bladder Cancerhttps://doi.org/10.1080/2162402X.2021.1912885 IL-15 Superagonist NAI in BCG-Unresponsive Non–Muscle-Invasive Bladder Cancerhttps://evidence.nejm.org/doi/full/10.1056/EVIDoa2200167 --- More about this episode This podcast is for informational purposes only. The views and opinions expressed in this podcast are solely those of the moderator and individual guest. --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

Dr. Yana Aznavour, CEO and Founder of Endometrics, discusses the significant diagnostic delay women face with endometriosis due to non-specific symptoms and the current reliance on invasive surgery for a definitive diagnosis. The company has developed a non-invasive at-home diagnostic test that uses menstrual blood to analyze a five-gene biomarker signature with high accuracy.  This objective, molecular-based test shortens the time to the correct treatment and changes the dynamic of the patient-doctor conversation. Yana explains, "We are developing non-invasive diagnostic tests, and we are primarily addressing the huge diagnostic delay that our patients, women, face, unfortunately. This happens because there are tons of non-specific symptoms and inconclusive imaging findings, and women face unnecessary appointments and procedures before reaching the point of definitive diagnosis. We are working rigorously towards bringing non-invasive, highly reliable diagnostic tests to help women get clarity and answers behind their symptoms way earlier in the journey."   "Menstrual pain and pain in general that women try to express and define at physician's appointments, it's being dismissed because they try to explain that, but in many cases, they cannot find exactly where it hurts, especially in endometriosis. Due to this, unfortunately, at the primary care level and the non-OB/GYN level, they're being dismissed and repeatedly misdiagnosed for years. The key reason is the non-specific symptoms because symptoms like pelvic pain and pain with urination overlap with the list of diagnoses. Currently, the definitive diagnosis for endometriosis is achieved through surgery. Nobody would do surgery after the first appointment. So, endometriosis becomes a diagnosis of exclusion, unfortunately, and it takes years before patients receive the final diagnosis." #Endometrics #Endometriosis, #WomensHealth, #Biomarkers, #Diagnostics, #FemTech #Gynecology #PrecisionMedicine endometrics.us Download the transcript here

Dr. Yana Aznavour, CEO and Founder of Endometrics, discusses the significant diagnostic delay women face with endometriosis due to non-specific symptoms and the current reliance on invasive surgery for a definitive diagnosis. The company has developed a non-invasive at-home diagnostic test that uses menstrual blood to analyze a five-gene biomarker signature with high accuracy.  This objective, molecular-based test shortens the time to the correct treatment and changes the dynamic of the patient-doctor conversation. Yana explains, "We are developing non-invasive diagnostic tests, and we are primarily addressing the huge diagnostic delay that our patients, women, face, unfortunately. This happens because there are tons of non-specific symptoms and inconclusive imaging findings, and women face unnecessary appointments and procedures before reaching the point of definitive diagnosis. We are working rigorously towards bringing non-invasive, highly reliable diagnostic tests to help women get clarity and answers behind their symptoms way earlier in the journey."   "Menstrual pain and pain in general that women try to express and define at physician's appointments, it's being dismissed because they try to explain that, but in many cases, they cannot find exactly where it hurts, especially in endometriosis. Due to this, unfortunately, at the primary care level and the non-OB/GYN level, they're being dismissed and repeatedly misdiagnosed for years. The key reason is the non-specific symptoms because symptoms like pelvic pain and pain with urination overlap with the list of diagnoses. Currently, the definitive diagnosis for endometriosis is achieved through surgery. Nobody would do surgery after the first appointment. So, endometriosis becomes a diagnosis of exclusion, unfortunately, and it takes years before patients receive the final diagnosis." #Endometrics #Endometriosis, #WomensHealth, #Biomarkers, #Diagnostics, #FemTech #Gynecology #PrecisionMedicine endometrics.us Listen to the podcast here

CardioNerds (Dr. Billy-Joe Mullinax, Dr. Dinu Balanescu, and Dr. Jane Ehret) discuss risk stratification in acute pulmonary embolism with Dr. Stavros Konstantinides, Chair of the 2019 ESC Pulmonary Embolism Guidelines. Using a real-world case, this episode explores how modern PE care has moved beyond “massive” and “submassive” labels toward a dynamic, physiology-based approach. The discussion highlights the limitations of static risk scores, the importance of right ventricular dysfunction and biomarkers, and why normotension does not imply stability. Special emphasis is placed on intermediate-high risk PE, early identification of impending hemodynamic collapse, and the role of lactate, serial reassessment, and PERT teams in guiding escalation of care. Audio editing by CardioNerds intern, Joshua Khorsandi.The 2026 American multi-society PE guidelines were published after this episode was recorded. Dr. Dinu Balanescu and Dr. Billy-Joe Mullinax are Co-chairs for the CardioNerds PE Series, developed in collaboration with the PERT Consortium.   Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. CardioNerds Pulmonary Embolism PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls Stable blood pressure does not mean low risk in PEHypotension is a late finding. Patients may have severe RV failure, hypoxia, and tissue hypoperfusion while remaining normotensive — a key concept behind “normotensive shock.” Risk stratification in PE must be dynamic, not staticLegacy scores like PESI and Bova provide a snapshot and predict 30-day mortality, but they do not capture short-term trajectory or impending hemodynamic collapse. Intermediate-high risk PE is a dangerous and heterogeneous groupPatients with RV dysfunction, positive biomarkers, tachycardia, hypoxemia, and elevated lactate may have in-hospital mortality approaching 15%, rivaling STEMI. Lactate is a critical but underutilized marker in PEElevated lactate reflects tissue hypoxia and early circulatory failure and may identify patients at risk for collapse before blood pressure declines. PERT enables physiology-driven, patient-centered PE carePERT teams operationalize continuous reassessment, integrate imaging, labs, and clinical trajectory, and allow timely escalation — shifting PE management from rigid categories to real-time decision-making. Notes Drafted by Dr. Jane Ehret. 1. What is the contemporary framework for risk stratification in acute pulmonary embolism? Modern PE risk stratification prioritizes hemodynamics and right ventricular (RV) function rather than clot burden. The 2019 ESC Guidelines classify PE into high risk, intermediate risk (low vs high), and low risk, based on: Hemodynamic status, RV dysfunction on imaging, and Cardiac biomarkers. This framework emphasizes early mortality risk but requires clinical context to guide escalation decisions. 2. Why is normotension insufficient to define “stability” in PE? Blood pressure is a late marker of circulatory failure in PE. Patients can maintain normal BP through Tachycardia, Increased sympathetic tone, and RV compensation. Many patients with preserved BP may already have shock physiology, including hypoxemia, elevated lactate, and RV failure — sometimes referred to as “normotensive shock.” 3. How should intermediate-risk PE be conceptualized clinically? Intermediate-risk PE is heterogeneous, ranging from patients who do well on anticoagulation to those who deteriorate rapidly. Intermediate-high risk PE is defined by RV dysfunction on imaging and positive cardiac biomarkers. Clinical features such as tachycardia, increasing oxygen requirement, and elevated lactate identify patients at highest risk within this group. 4. What are the strengths and limitations of commonly used PE risk scores? Legacy scores are useful for initial risk categorization but are static and limited in predicting short-term deterioration. Most scores were developed to predict mortality or complications at fixed time points rather than dynamic clinical trajectory. 5. What are the commonly used risk scores and clinical tools in PE, and what is each designed to predict? ESC Risk Stratification Algorithm: Identifies high-risk PE by hemodynamics. Uses PESI or sPESI in normotensive patients to distinguish low-risk from non–low-risk PE. Uses RV dysfunction and biomarkers to differentiate intermediate-low from intermediate-high risk. Forms the basis of many institutional PE pathways. PESI and sPESI: Validated to predict 30-day mortality. Widely used to identify low-risk patients appropriate for outpatient management. Heavily influenced by age and comorbidities. Bova Score: Predicts 30-day PE-related complications in normotensive patients. Composite PE Shock Score (CPES): Predicts normotensive shock in hemodynamically stable PE patients. Pulmonary Embolism Progression (PEP) Score: Predicts progression from intermediate-risk to high-risk PE within 72 hours of diagnosis. PE Short-term Clinical Outcomes Risk Estimation (PE-SCORE): Predicts clinical deterioration or death within 5 days of PE diagnosis. Hestia Criteria: Identifies low-risk PE patients safe for outpatient treatment. Wells' Criteria and Revised Geneva Score: Determine pretest probability for diagnostic triage. PERC Score: Rules out PE in very low-risk patients. 6. What is the role of biomarkers in PE risk stratification? Troponin and natriuretic peptides reflect RV myocardial injury and strain. Current guidelines treat biomarkers as binary (positive vs negative), despite risk being continuous. Biomarkers are most helpful for: Initial risk classification. They are less useful for: Short-interval monitoring and Detecting rapid clinical deterioration. 7. Why is lactate an important physiologic marker in PE? Lactate reflects global tissue hypoxia and impaired perfusion. Elevated lactate may identify patients with: Early circulatory failure and Increased risk of imminent hemodynamic collapse. Lactate is not currently included in ESC risk algorithms but may add important prognostic information in intermediate-risk patients. 8. How does trajectory influence decision-making in PE management? Risk stratification should be viewed as a dynamic process, not a one-time label. Worsening clinical trajectory may include: Rising heart rate, Increasing oxygen needs, Rising lactate, and Progressive RV dysfunction. Serial reassessment is essential for timely escalation of care. 9. What role do Pulmonary Embolism Response Teams (PERT) play in risk stratification? PERT facilitates: Multidisciplinary decision-making and Integration of imaging, biomarkers, and clinical physiology. PERT is most valuable for: Intermediate-risk and high-risk PE and Patients with complex comorbidities or uncertain trajectory. PERT enables a shift from category-based to physiology-driven PE care. References 1. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Respir J. 2019;54(3):1901647. Published 2019 Oct 9. doi:10.1183/13993003.01647-2019 2. Leidi A, Bex S, Righini M, Berner A, Grosgurin O, Marti C. Risk Stratification in Patients with Acute Pulmonary Embolism: Current Evidence and Perspectives. J Clin Med. 2022;11(9):2533. Published 2022 Apr 30. doi:10.3390/jcm11092533 3. Choi WH, Kwon SU, Jwa YJ, et al. The pulmonary embolism severity index in predicting the prognosis of patients with pulmonary embolism. Korean J Intern Med. 2009;24(2):123-127. doi:10.3904/kjim.2009.24.2.123 4. Jiménez D, Aujesky D, Moores L, et al. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med. 2010;170(15):1383-1389. doi:10.1001/archinternmed.2010.199 5. Chen X, Shao X, Zhang Y, et al. Assessment of the Bova score for risk stratification of acute normotensive pulmonary embolism: A systematic review and meta-analysis. Thromb Res. 2020;193:99-106. doi:10.1016/j.thromres.2020.05.047 6. Zhang RS, Yuriditsky E, Zhang P, et al. Composite Pulmonary Embolism Shock Score and Risk of Adverse Outcomes in Patients With Pulmonary Embolism. Circ Cardiovasc Interv. 2024;17(8):e014088. doi:10.1161/CIRCINTERVENTIONS.124.014088 7. Zhang RS, Alam U, Sharp ASP, et al. Validating the Composite Pulmonary Embolism Shock Score for Predicting Normotensive Shock in Intermediate-Risk Pulmonary Embolism. Circ Cardiovasc Interv. 2024;17(2):e013399. doi:10.1161/CIRCINTERVENTIONS.123.013399 8. Ehret J, Wakefield D, Badlam J, Antkowiak M, Erdreich B. Development of the Pulmonary Embolism Progression (PEP) score for predicting short-term clinical deterioration in intermediate-risk pulmonary embolism: a single-center retrospective study. J Thromb Thrombolysis. 2025;58(2):243-253. doi:10.1007/s11239-024-03051-5 9. Weekes AJ, Raper JD, Lupez K, et al. Development and validation of a prognostic tool: Pulmonary embolism short-term clinical outcomes risk estimation (PE-SCORE). PLoS One. 2021;16(11):e0260036. Published 2021 Nov 18. doi:10.1371/journal.pone.0260036 10. Zondag W, Hiddinga BI, Crobach MJ, et al. Hestia criteria can discriminate high- from low-risk patients with pulmonary embolism. Eur Respir J. 2013;41(3):588-592. doi:10.1183/09031936.00030412 11. Wells PS, Anderson DR, Rodger M, et al. Excluding pulmonary embolism at the bedside without diagnostic imaging: management of patients with suspected pulmonary embolism presenting to the emergency department by using a simple clinical model and d-dimer. Ann Intern Med. 2001;135(2):98-107. doi:10.7326/0003-4819-135-2-200107170-00010 12. Wolf SJ, McCubbin TR, Feldhaus KM, Faragher JP, Adcock DM. Prospective validation of Wells Criteria in the evaluation of patients with suspected pulmonary embolism. Ann Emerg Med. 2004;44(5):503-510. doi:10.1016/j.annemergmed.2004.04.002 13. Le Gal G, Righini M, Roy PM, et al. Prediction of pulmonary embolism in the emergency department: the revised Geneva score. Ann Intern Med. 2006;144(3):165-171. doi:10.7326/0003-4819-144-3-200602070-00004 14. Kline JA, Mitchell AM, Kabrhel C, Richman PB, Courtney DM. Clinical criteria to prevent unnecessary diagnostic testing in emergency department patients with suspected pulmonary embolism. J Thromb Haemost. 2004;2(8):1247-1255. doi:10.1111/j.1538-7836.2004.00790.x 15. Kline JA, Courtney DM, Kabrhel C, et al. Prospective multicenter evaluation of the pulmonary embolism rule-out criteria. J Thromb Haemost. 2008;6(5):772-780. doi:10.1111/j.1538-7836.2008.02944.x

In this first deep dive, Rachel Buckley joins host Catherine Glass to explore how Alzheimer's disease risk can be detected before symptoms appear. From blood-based biomarkers like p-tau217, to AI-driven models of cognitive resilience, the episode examines how risk, progression, and protection can be better understood and predicted over time. Timestamps: 00:00:57:11 – Phosphorylated tau and amyloid-PET 00:08:15:05 – Biomarkers, risk, and progression 00:11:18:04 – Brain resistance and cognitive resilience 00:15:23:23 – AI biases

In this episode of Joint Ventures, hosts Jack Arnold, MBBS, PhD, an academic clinical lecturer in rheumatology at the University of Leeds, and Rihards Buss, MD, a consultant rheumatologist at Freeman Hospital, Newcastle, preview their unofficial countdown of the sessions, themes, and abstracts they are most excited about heading into the 2026 European Alliance of Associations for Rheumatology (EULAR) Annual Meeting in London, June 3–6, including:  Obesity, Weight Management, and Psoriatic Arthritis Sessions Personalized Medicine and Biomarkers in RMDs Sessions Fatigue and Quality of Life in Connective Tissue Disease Session Mitochondrial DNA and Interferon: Upstream Drivers of Autoimmunity Session Artificial Intelligence and Pattern Recognition in Rheumatology Sessions Axial Imaging in Axial Spondyloarthritis Session Head-to-Head Superiority Trials in RA and PsA Sessions CAR-T and CAR-NK Therapies: Efficacy, Limits, and What Comes Next Sessions

In this week's episode, Blood editor Dr. James Griffin interviews Drs. Johnny Mahlangu and Joseph Rocco on their articles published in volume 147 issue 9 of Blood.  Dr. Mahlangu discusses study details and next steps from "Efficacy and safety of marstacimab prophylaxis in hemophilia A/B with inhibitors: results from the phase 3 BASIS trial" which shows that bleeding was reduced by 93% with subcutaneous marstacimab. Dr. Rocco shares the development behind "CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis", and the insights gained from measuring a new surrogate marker of IFN-γ activity predicting severity and mortality.

In this episode I look at blood tests that tell us about what's going on with our biological processes in terms of our long term metabolic health and the blood markers are relevant.Hba1c control: https://pmc.ncbi.nlm.nih.gov/articles/PMC4933534/Fasting insulin: https://pubmed.ncbi.nlm.nih.gov/11118012/Vitamin D: https://pmc.ncbi.nlm.nih.gov/articles/PMC10002864/AST/ALT: https://pmc.ncbi.nlm.nih.gov/articles/PMC10346959/Triglycerides and HDL ratio: https://pmc.ncbi.nlm.nih.gov/articles/PMC11493158/ApoB: https://pmc.ncbi.nlm.nih.gov/articles/PMC11219008/HDL cholesterol: https://pmc.ncbi.nlm.nih.gov/articles/PMC6077683/Hs-CRP: https://pmc.ncbi.nlm.nih.gov/articles/PMC9650935/Homocysteine: https://pmc.ncbi.nlm.nih.gov/articles/PMC12564181/Uric Acid: https://pmc.ncbi.nlm.nih.gov/articles/PMC8624633/Do Health: https://dohealth.co/what-we-measure#wwm-step-1Save your life in slow motion and those of others by subscribing now and sharing. Thank you for listening and for your support. It means a lot to me. Hosted on Acast. See acast.com/privacy for more information.

AUA2026: Focus on: Biomarkers, MRI and PSMA PET Imaging in Prostate Cancer Webcast CME Available: https://cme.auanet.org/URL/FOCUS262ONL LEARNING OBJECTIVES: After participating in this CME activity, participants will be able to: 1. Critically appraise recent developments in imaging biomarkers and molecular diagnostics (e.g., genomic risk scores, liquid biopsy) and discuss how they complement MRI and PSMA PET in prostate cancer care. 2. Determine the optimal clinical scenarios (diagnostic, staging, recurrence, surveillance) in which PSMA PET/CT or PET/MRI adds value beyond conventional imaging. 3. Recognize potential pitfalls in PSMA PET interpretation — including false positives, false negatives, non–PSMA-expressing disease, and technical artifacts — and implement strategies to mitigate them. 4. Synthesize biomarker, MRI, and PSMA PET findings into a personalized management plan, including guiding biopsy, focal therapy, salvage therapy, or systemic treatments. 5. Select appropriate patients with radiorecurrent or organ-confined prostate cancer for advanced imaging and guide re-treatment decisions (e.g., salvage therapy, targeted radiotherapy). ACKNOWLEDGEMENTS: Support provided by independent educational grants from: Blue Earth Diagnostics, Inc. Lantheus Medical Imaging

Sepsis care is evolving fast. Are you keeping up? Don't miss this podcast episode, where we explore the latest clinical trials reshaping antibiotic therapy for severe infections, from optimised treatment durations to precision-driven de-escalation strategies. What does this new evidence mean for your day-to-day decisions in the ICU?We then turn to one of the most exciting frontiers in intensive care: biomarkers, and how they are transforming the way clinicians diagnose, monitor, and guide therapy in sepsis.Tune in to gain key insights and practical knowledge to help you bring the science of today directly to the bedside.

Making Diet Changes Without Extremes; Simplify for Sustainability and Social Connection; Three-Hour Sitting Rule Applies to the Sedentary; Importance of Moving Regularly; Value of Biomarkers vs. Observable Health; Be Cautious with Doctor Visits and Over-Testing; Yoga vs. Weight Training for Bone Strength; Bone Strength Can Improve Quickly with Exercise; Late-Life Exercise Still Effective; Most Supplements Are Unnecessary; Natural Medicine Replaced by Pill-Based Wellness; Fruits, Not Pills, Cured Nutrient Deficiencies Historically; Isolated Powders Lack Traditional Context; Most 'Evidence' for Supplements is Weak #HealthyAging #Longevity #BrainHealth #HealthTalks

We all know our four vital signs and how to take our heart rate, but what about reproductive vital signs? Are there any? YES and they're called reproductive biomarkers. Today's episode lays out the key biomarkers that you can use in your daily life for family planning and health diagnosis (as well as bonus ones that may be more specific to you).Looking for help finding the right method of tracking reproductive biomarkers for you? Our new book, Woven Well: A Christian Woman's Guide for Reproductive Health, Fertility, and Wholeness is here to help! You can pre-order the book now through these links or call your local book store to request it!NOTE: This episode is appropriate for most audiences but does refer to sex education and uses the word 'libido.'SHOW NOTES: **Pre-order Woven Well: A Christian Woman's Guide for Reproductive Health, Fertility, and Wholeness here: https://www.wovenfertility.com/pre-order-woven-wellJoin us for an upcoming Intro Session Ep. 212: Traditional Chinese Medicine explains period blood clots, with guest Emily Keuntz, M.S., L.Ac.Send Us a Text!Support the showOther great ways to connect with Woven Natural Fertility Care: Learn the Creighton Model System with us! Register here!Get our monthly newsletter: Get the updates!Chat about issues of fertility + faith: Substack Follow us on Instagram: @wovenfertilityWatch our episodes on YouTube: @wovenfertilityLove the content? The biggest gift you could give is to click a 5 star review and write why it was so meaningful! This podcast is provided for educational and informational purposes only and does not constitute providing medical advice or professional services. The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician. Always seek the advice of your doctor or other qualified health provider regarding a medical condition. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. Neither Woven nor its staff, nor any contributor to this podcast, makes any representations, exp...

Program notes:0:37 Prehospital resuscitation with whole blood1:37 Compared with blood components2:35 Easier to store 3:19 Azithromycin in wheezing kids4:19 Treated for five days5:26 Name change from PCOS to PMOS6:26 Consensus build7:28 Improved accuracy of pathophysiology8:30 Adjust policy, change international classification9:15 Biomarkers to direct lung cancer screening10:15 Participants from several countries11:15 What are barriers to those with a smoking history12:24 End

Editor's Summary by Preeti Malani, MD, MSJ, and Tracy Lieu, MD, MPH, Deputy Editors of JAMA, the Journal of the American Medical Association, for articles published from May 16-22, 2026.

From the World Congress of Anesthesiologists in Marrakech, TopMedTalk hosts Mike Grocott and Kate Leslie discuss perioperative cardiac risk assessment with Hilary Grocott, Professor and Head of, The Department of Anesthesiology, Pharmacology & Therapeutics (University of British Columbia) and Michelle Chew Professor of Anesthesiology and Intensive Care Medicine at Karolinska Institutet, Stockholm, Sweden, and editor for the British Journal of Anaesthesia. The conversation reviews perioperative cardiac biomarkers, noting abundant prognostic data but limited evidence for biomarker-led management. The discussion emphasizes that elevated troponins can reflect non-cardiac complications (AKI, PE, sepsis) as well as myocardial injury or heart failure, requiring context-specific follow-up pathways. The group highlights NT-proBNP as a specific marker for heart failure and useful for screening and optimization. The podcast then focuses on pulmonary hypertension and failing right ventricle: detect via history, exam, echo, and biomarkers; prioritize preemptive preparation, arterial beat-to-beat monitoring, modest fluids, early vasopressors/inotropes (norepinephrine, low-dose epinephrine), ventilatory optimization, and vigilant, rapid intervention. If you enjoyed this piece there's a fantastic Perioperative Profile with Michelle Chew you can hear here: https://topmedtalk.libsyn.com/perioperative-profiles-professor-michelle-chew-on-seizing-opportunities-in-anaesthesia-research-editing-and-guideline-work -- Join us at Evidence Based Perioperative Medicine (EBPOM) World Congress 2026 in London. Be part of a global conversation as clinicians from around the world gather between 7-9th July at the British Library in London. Three days of evidence-based perioperative medicine, global insights, and expert debate—featuring speakers including Michael Marmot and Ken Rockwood. Register here - https://ebpom.org/product/ebpom-world-congress-2026/

Gina, a perinatal fitness trainer, birth doula, and founder of MamasteFit in North Carolina, explains how exercising during pregnancy improves quality of life during pregnancy and postpartum—not just birth outcomes—while noting prenatal exercise research is still limited. She highlights a 2025/2026 American Journal of Obstetrics and Gynecology systematic review (11 RCTs) finding the strongest biomarker benefits from 12+ week programs done 2–3 times/week at moderate-to-vigorous intensity, including reduced pro-inflammatory markers, improved glucose/insulin regulation (supporting lower gestational diabetes risk), better lipid regulation, and favorable hormone/growth-factor changes linked to placental function and possibly baby brain development. Another 2025 review (9 RCTs, 1,500+ participants) suggests strength training may reduce excessive weight gain, low back/sciatic pain, and improve mood, sleep, fatigue, and well-being. She also cites studies indicating high-intensity lifting and even Valsalva can be well-tolerated with adequate rest and self-monitoring, then outlines MamasteFit's endurance-focused programming (compound lifts, accessory multi-plane work, myofascial slings, and posterior-chain emphasis) and promotes their app/video programs with a discount code.00:00 Why Prenatal Exercise Matters00:46 Meet Gina and MamasteFit01:38 What Research Can Tell Us02:23 Biomarkers and Training Dose05:11 Inflammation and Glucose Control08:05 Lipids Hormones and Baby Brain10:46 Strength Training Quality of Life13:17 Heavy Lifting and Valsalva Safety18:03 Listening to Your Body18:58 How to Program Prenatal Lifting20:54 Movement Variety and Posterior Chain23:04 Programs and Final Takeaways————

Each month, we will highlight a paper published in Aging-US chosen as the “Editors' Choice.” These selections are handpicked by our editors and accompanied by a brief summary, showcasing research with significant impact and novel insights in aging and age-related diseases. __________ In the research paper, titled “Association of epigenetic age acceleration with MRI biomarkers of aging and Alzheimer's disease neurodegeneration,” researchers investigated whether epigenetic clocks of biological aging are associated with MRI markers of brain aging and Alzheimer's disease-related neurodegeneration in 1,196 older women. While none of the five epigenetic clocks examined were linked to accelerated overall brain aging, one measure (AgeAccelGrim2) was associated with MRI patterns related to neurodegeneration. The findings suggest this relationship was largely driven by DNA methylation markers linked to smoking history and changes in frontal and temporal brain regions rather than areas typically affected early in Alzheimer's disease. Overall, the study indicates that epigenetic aging and brain aging may reflect different aspects of the aging process, while highlighting the potential role of smoking-related biological aging in increasing dementia risk. DOI - https://doi.org/10.18632/aging.206369 Corresponding author - Linda K. McEvoy - linda.k.mcevoy@kp.org Abstract video - https://www.youtube.com/watch?v=kZiRjlKnnsI Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206369 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, epigenetic clocks, brain age, biological aging, smoking, frontal lobe To learn more about the journal, please visit https://www.Aging-US.com​​ and connect with us on social media at: Bluesky - https://bsky.app/profile/aging-us.bsky.social ResearchGate - https://www.researchgate.net/journal/Aging-1945-4589 X - https://twitter.com/AgingJrnl Facebook - https://www.facebook.com/AgingUS/ Instagram - https://www.instagram.com/agingjrnl/ LinkedIn - https://www.linkedin.com/company/aging/ Reddit - https://www.reddit.com/user/AgingUS/ Pinterest - https://www.pinterest.com/AgingUS/ YouTube - https://www.youtube.com/@Aging-US Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

Find out how to avoid toxins in oils and processed foods, boost resilience with teas and glutathione, and detect disease early. #ToxinFreeLiving #EarlyDetection #HealthyAging #HealthTalks

This episode covers: Cardiology This Week: A concise summary of recent studies Biomarkers in heart failure Digoxin in HFrEF Scientific Highlights from Heart Failure 2026 Host: Wilfried Mullens Guests: Lynne Stevenson, Dirk van Veldhuisen, Theresa McDonagh Want to watch that episode? Go to: https://esc365.escardio.org/event/2565 Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. A ny views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel, Dirk van Veldhuisen and Lynne Warner Stevenson have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report:Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi.  Theresa McDonagh has declared to have potential conflicts of interest to report: honoraria from Boeringer Ingelheim. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

The episode explains that inflammation is a necessary survival mechanism, with acute inflammation supporting healing, while chronic inflammation drives chronic disease. It outlines major contributors to chronic inflammation including visceral fat (with fasting insulin as a proxy for insulin resistance), poor sleep and sleep apnea, ultra-processed foods, sedentary behavior, overtraining, chronic psychological stress, poor oral health, gut dysbiosis/barrier issues, smoking, alcohol, pollution, autoimmune disease, and chronic infection. The host reviews biomarkers to discuss with a physician such as high-sensitivity CRP, ESR, ferritin, WBC and neutrophil-to-lymphocyte ratio, fasting insulin, ApoB, omega-3 index/omega-6:omega-3 ratio, and homocysteine. Chronic inflammation is linked to cardiovascular disease, depression/anhedonia, brain fog, autoimmune disease risk, cancer mechanisms, skin aging, erectile dysfunction, and chronic pain. Treatment focuses on lifestyle (notably treating sleep apnea, sleep optimization, fat loss, exercise, oral health, omega-3 intake, sauna, stress regulation, circadian rhythm), selected supplements (vitamin D if deficient, curcumin, boswellia, ginger, garlic, olive oil polyphenols, sulforaphane, magnesium/glycine, taurine, NAC, quercetin, probiotics, creatine), and brief discussion of drugs including GLP-1 agonists, colchicine, NSAIDs, corticosteroids, and biologics.   Chronic inflammation https://www.ncbi.nlm.nih.gov/books/NBK493173/ C-reactive protein test https://medlineplus.gov/lab-tests/c-reactive-protein-crp-test/ ESR blood test https://medlineplus.gov/lab-tests/erythrocyte-sedimentation-rate-esr/ Ferritin blood test https://medlineplus.gov/lab-tests/ferritin-blood-test/ Homocysteine test https://medlineplus.gov/lab-tests/homocysteine-test/ ApoB test https://my.clevelandclinic.org/health/diagnostics/24992-apolipoprotein-b-test Insulin resistance https://www.ncbi.nlm.nih.gov/books/NBK507839/ Obstructive sleep apnea https://medlineplus.gov/ency/article/000811.htm CPAP therapy https://medlineplus.gov/ency/article/001916.htm Sleep hygiene https://www.cdc.gov/sleep/about_sleep/sleep_hygiene.html Physical activity guidelines https://www.cdc.gov/physical-activity-basics/guidelines/adults.html Ultra-processed foods https://pmc.ncbi.nlm.nih.gov/articles/PMC10831891/ Gum disease https://www.cdc.gov/oral-health/about/gum-periodontal-disease.html Gut microbiome https://www.nccih.nih.gov/health/gut-microbiome-what-you-need-to-know Fiber https://www.hsph.harvard.edu/nutritionsource/carbohydrates/fiber/ Autoimmune diseases https://medlineplus.gov/autoimmunediseases.html Inflammation and heart disease https://www.heart.org/en/health-topics/consumer-healthcare/what-is-cardiovascular-disease/inflammation-and-heart-disease Inflammation and depression https://pmc.ncbi.nlm.nih.gov/articles/PMC4566946/ Cancer and chronic inflammation https://www.cancer.gov/about-cancer/causes-prevention/risk/chronic-inflammation Omega-3 supplements https://www.nccih.nih.gov/health/omega3-supplements-what-you-need-to-know   Show Notes 00:00 Welcome to the Hart2Heart Podcast 00:58 Inflammation Basics 01:24 Acute Versus Chronic 03:29 Chronic Disease Link 03:52 Visceral Fat Driver 06:06 Sleep And Apnea 12:33 Food And Movement 16:02 Stress And Oral Health 18:17 Gut And Fiber 21:17 Toxins Autoimmune Infection 26:05 Inflammation Biomarkers 27:13 Inflammation Blood Markers 28:37 Ferritin Iron Balance 30:07 Metabolic Cardio Labs 32:08 Omega 3 Index Insights 34:07 Homocysteine Risks 34:58 Why Inflammation Matters 41:07 Lifestyle Fixes 46:24 Supplement Options 54:36 Medication Overview 57:36 Final Takeaways   The Hart2Heart podcast is hosted by family physician Dr. Michael Hart, who is dedicated to cutting through the noise and uncovering the most effective strategies for optimizing health, longevity, and peak performance. This podcast dives deep into evidence-based approaches to hormone balance, peptides, sleep optimization, nutrition, psychedelics, supplements, exercise protocols, leveraging sunlight, and de-prescribing pharmaceuticals — using medications only when absolutely necessary. Beyond health science, we explore the intersection of public health and politics, exposing how policy decisions shape our health landscape and what actionable steps people can take to reclaim control over their well-being. Guests range from out-of-the-box thinking physicians such as Dr. Casey Means (author of "Good Energy") and Dr. Roger Sehult (Medcram lectures) to public health experts such as Dr. Jay Bhattacharya (Director of the National Institutes of Health (NIH) and Dr. Marty Mckary  (Commissioner of the Food and Drug Administration (FDA) and high-profile names such as  Zuby and Mark Sisson (Primal Blueprint and Primal Kitchen). If you're ready to take control of your health and performance, this podcast is for you.We cut through the jargon and deliver practical, no-BS advice that you can implement in your daily life, empowering you to make positive changes for your well-being. Connect with Dr. Mike Hart Instagram: @drmikehart Twitter: @drmikehart Facebook: @drmikehart

In the second part of this series, Dr. Katie Krulisky and Dr. Cristina Domínguez-González explore the most effective approach to evaluating suspected mitochondrial disease. Show citation: Bermejo-Guerrero L, Restrepo-Vera JL, Martin-Jimenez P, et al. Clinical Heterogeneity and Candidate Biomarkers in POLG-Related Mitochondrial Disease. Neurol Genet. 2026;12(2):e200365. Published 2026 Mar 10. doi:10.1212/NXG.0000000000200365  Show transcript:  Dr. Katie Krulisky: This is The Neurology Minute. This is the second part of our series. I'm Katie Krulisky from the University of Utah and I'm here with Cristina Domínguez-González from the 12th of October University Hospital and its affiliated health research institute in Madrid, Spain. We've just recorded a full podcast on our paper, Clinical Heterogeneity and Candidate Biomarkers in POLG-related Mitochondrial Disease, which has been published in Neurology Genetics. Cristina, for The Minute, what's the most practical way to work up suspected mitochondrial disease today? Dr. Cristina Domínguez-González:  In practice, everything starts with the clinical picture. Recognizing the pattern, whether it's a combination of features or a more subtle isolated presentation, is what should first raise suspicion. From there, you decide the next step. Targeted genetic testing if the phenotype is well-defined, grow their sequencing if it is less clear or more complex. Biomarkers can also be very helpful. GDF15, Growth Differentiation Factor 15, is markedly elevated in many mitochondrial diseases and can support the suspicion. In myopathies in particular, it is especially useful because of its high negative predictive value helping to rule out a mitochondrial cause when levels are not elevated. And finally, muscle biopsy still has a role. It can provide important information in selected cases, particularly in adults or when genetic results are inconclusive, both for diagnosis and also to guide further studies. Dr. Katie Krulisky: Thank you. That's super helpful. And for more on mitochondrial diseases and POLG-related disorders, have a listen to the full neurology podcast. Again, I'm Katie Krulisky from the University of Utah with Cristina Domínguez-González  from the 12th of October University Hospital and its affiliated health research institute in Madrid, Spain.  

In this episode of the IDEA Collider, host Mike Rea sits down with Reagan Jarvis, scientific founder and CEO of Anocca, to explore how TCR-T cell therapy could unlock the next frontier in cancer treatment—particularly for solid tumors.  While CAR-T therapy has transformed outcomes in hematologic cancers, its success has been limited in solid tumors due to a lack of suitable targets. Reagan explains how T-cell receptor (TCR) therapies overcome this challenge by targeting HLA-presented peptide antigens, enabling access to tumor-specific biology that CAR-T cannot reach.  Anocca is building a fully integrated platform that combines: Target mapping of HLA-peptide complexes Rapid generation of optimized T-cell receptors from healthy donors Non-viral gene editing for faster, lower-cost manufacturing End-to-end control from discovery through clinical development. The conversation also highlights Anocca's first clinical program targeting mutant KRAS in pancreatic ductal adenocarcinoma, using an umbrella trial design, early intervention strategies, and biomarkers such as circulating tumor DNA (ctDNA). Reagan shares insights on regulatory pathways for individualized therapies, the commercial challenges of patient segmentation, and how software, data, and machine learning are becoming essential to scaling cell therapy platforms.  This episode is a must-listen for anyone interested in cell therapy innovation, cancer immunotherapy, and the future of precision medicine.  Episode Timestamps  00:00 – Introduction to TCR-T and solid tumor challenges  00:48 – Meet Reagan Jarvis and Anocca  02:05 – From New Zealand to Sweden: founder journey  03:08 – Frustration that sparked the platform  04:33 – Why CAR-T struggles in solid tumors  07:24 – The advantage of vertical integration in biotech  09:23 – First non-viral clinical trial challenges  10:56 – Umbrella trials in pancreatic cancer (KRAS focus)  14:13 – Biomarkers and building a target library  17:08 – Software, data, and machine learning in TCR discovery  18:08 – Regulatory pathways for individualized therapies  19:19 – Commercial landscape and target bottlenecks  22:29 – Expanding beyond oncology and partnerships  23:51 – Building a biotech company in Sweden  27:12 – Misconceptions about T-cell biology  30:04 – Milestones and 5-year vision  32:32 – Advice for scientific founders  34:17 – Closing thoughts  Don't forget to Like, Share, Subscribe, Rate, and Review!      Keep up with Reagan Jarvis;  LinkedIn: https://www.linkedin.com/in/reagan-jarvis-063984142/  Website: https://www.anocca.com/     Follow IDEA Pharma  Website: https://www.ideapharma.com/  LinkedIn: https://www.linkedin.com/company/idea-pharma/   Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

What if your genes are not your destiny, but a set of clues your body has been giving you all along? In this episode, Dr. Taz sits down with Dr. Florence Comite, endocrinologist, clinician scientist, longevity expert, and author of Invincible: Defy Your Genetic Destiny to Live Better, Longer, to explore how biomarkers, genetics, hormones, sleep, metabolism, and family history shape the way we age.In this episode, Dr. Comite explains why longevity is not just about biohacking, supplements, peptides, or the latest wellness trend. Instead, she shares why true healthspan begins with understanding your own body, your own patterns, and your own family story. She explains how changes in blood sugar, fasting insulin, free testosterone, cholesterol risk ratio, sleep quality, muscle, and metabolism can reveal early signs of disease risk long before symptoms fully appear.Dr. Taz and Dr. Comite discuss why “normal” lab ranges are not always the same as optimal health, why some people begin showing signs of metabolic disease decades earlier than expected, and how family history can act as a powerful roadmap for prevention. They also explore how genetics, lifestyle, hormones, wearables, continuous glucose monitoring, sleep, movement, protein, and personalized medicine may help people change the trajectory of their future health.If you're listening to this and thinking, “I know something is off in my body, but I don't know where to start,” join the Circle here:

Up to 200 million people worldwide may be living with undiagnosed mild cognitive impairment – many unaware that early intervention could change their trajectory. In this episode, host Alex Maiersperger is joined by Marc Jones, CEO of Altoida, and Dr. Mona Flores of Altoida's Clinical Advisory Board to explore how AI and digital biomarkers are reshaping early detection of cognitive decline. Digital biomarkers register how the brain processes information, translating how brain networks function through the way we move, speak and remember. Altoida's platform tracks motor skills, speech complexity and memory recall, mapping them to data points to identify where brain function diverges from that of a healthy population. They also discuss how AI acts as a force multiplier, giving clinicians tools to spot trends, make informed decisions and spend more time with patients.

If you enjoy this episode, we're sure you will enjoy more content like this on The Occult Rejects.  In fact, we have curated playlists on occult topics like grimoires, esoteric concepts and phenomena, occult history, analyzing true crime and cults with an occult lens, Para politics, and occultism in music. Whether you enjoy consuming your content visually or via audio, we've got you covered - and it will always be provided free of charge.  So, if you enjoy what we do and want to support our work of providing accessible, free content on various platforms, please consider making a donation to the links provided below.  Thank you and enjoy the episode!Links For The Occult Rejectshttps://linktr.ee/theoccultrejectsOccult Research Institutehttps://www.occultresearchinstitute.org/Cash Apphttps://cash.app/$theoccultrejectsVenmo@TheOccultRejectsBuy Me A Coffeebuymeacoffee.com/TheOccultRejectsPatreonhttps://www.patreon.com/TheOccultRejects1. Patel, A. K., et al. *Physiology, Sleep Stages*. StatPearls / NCBI Bookshelf, 2024.2. Jensen, O., & Mazaheri, A. “Shaping Functional Architecture by Oscillatory Alpha Activity: Gating by Inhibition.” *Frontiers in Human Neuroscience*, 2010.3. Cavanagh, J. F., & Shackman, A. J. “Frontal Midline Theta Reflects Anxiety and Cognitive Control: Meta-Analytic Evidence.” *Journal of Physiology-Paris*, 2015.4. Axmacher, N., et al. “Cross-Frequency Coupling Supports Multi-Item Working Memory in the Human Hippocampus.” *PNAS*, 2010.5. Lacaux, C., et al. “Sleep Onset Is a Creative Sweet Spot.” *Science Advances*, 2021.6. Horowitz, A. H., et al. “Targeted Dream Incubation at Sleep Onset Increases Post-Sleep Creative Performance.” *Scientific Reports*, 2023.7. Caporro, M., et al. “Functional MRI of Sleep Spindles and K-Complexes.” *Clinical Neurophysiology*, 2012.8. Ng, T., et al. “Bayesian Meta-Analysis Reveals the Mechanistic Role of Slow Oscillation-Spindle Coupling in Sleep-Dependent Memory Consolidation.” *eLife*, 2025.9. Datta, K., et al. “Electrophysiological Evidence of Local Sleep During Yoga Nidra Practice in Young Male Volunteers.” *Frontiers in Neurology*, 2022.10. Jensen, M. P., et al. “Brain Oscillations, Hypnosis, and Hypnotizability.” *American Journal of Clinical Hypnosis*, 2015.11. Huels, E. R., et al. “Neural Correlates of the Shamanic State of Consciousness.” *Frontiers in Human Neuroscience*, 2021.12. Ingendoh, R. M., et al. “Binaural Beats to Entrain the Brain? A Systematic Review...” *PLOS ONE*, 2023.13. Páez, A., et al. “Sleep Spindles and Slow Oscillations Predict Cognition and Biomarkers of Neurodegeneration in Mild to Moderate Alzheimer's Disease.” *Alzheimer's & Dementia*, 2025.14. Askitopoulou, H. “Sleep and Dreams: From Myth to Medicine in Ancient Greece.” *Journal of Anesthesia History*, 2015.15. Pavli, A. “Asclepieia in Ancient Greece: Pilgrimage and Healing.” *Journal of Integrative Medicine and Research*, 2024.Also want to remind people about the website, if you're into reading we have tons of information by multiple contributors, and we got t-shirts up on the site if you're interested. Fun fact, the art is all based on the eyeball. Now let me introduce the rest of the panel and guests.

In part one of this series, Dr. Katie Krulisky and Dr. Cristina Domínguez-González discuss when a neurologist should start thinking about mitochondrial disease.  Show citation: Bermejo-Guerrero L, Restrepo-Vera JL, Martin-Jimenez P, et al. Clinical Heterogeneity and Candidate Biomarkers in POLG-Related Mitochondrial Disease. Neurol Genet. 2026;12(2):e200365. Published 2026 Mar 10. doi:10.1212/NXG.0000000000200365  Show transcript:  Dr. Katie Krulisky: This is The Neurology Minute, and this will be a two-part series. I've had the pleasure of speaking with Cristina Domínguez-González from the 12th of October University Hospital and its affiliated Health Research Institute in Madrid, Spain. I'm Katie Krulisky from the University of Utah. We've just recorded a full podcast on our paper, Clinical Heterogeneity and Candidate Biomarkers and POLG-related Mitochondrial Disease, which has been published in Neurology Genetics. So for our first minute, Cristina, when should a neurologist start thinking about mitochondrial disease? Dr. Cristina Domínguez-González: Mitochondrial diseases are among the most common inherited neurological disorders. Think of them whenever you see compatible features like ptosis ophthalmoplegia, polyneuropathy, ataxia or myopathy, especially when they occur in combination. But even when these features appear in isolation, mitochondrial disease should still be part of the differential. This is particularly important because many patients do not present with a full classical picture, especially in early the disease course. In practice, this means maintaining a low threshold to consider mitochondrial disease, even in a typical presentations. Dr. Katie Krulisky: Thank you so much. And for more information on mitochondrial disease and POLG-related disorders, do listen to the full neurology podcast. Again, I'm Katie Krulisky from the University of Utah with Cristina Domínguez-González from the 12th of October University Hospital and its affiliated Health Research Institute in Madrid, Spain.   

Dr. Katie Krulisky talks with Dr. Cristina Domínguez-González about the complexities of mitochondrial disease, including diagnosis, biomarkers, and recent research on POLG-related disorders.  Read the related article in Neurology® Genetics.  Disclosures can be found at Neurology.org.

In this episode of the Epigenetics Podcast, we talked with Alena van Bömmel from the Biomedical Center (BMC) in Munich about her work on the development of interpretable epigenetic clocks and statistical models of epigenetic dynamics during aging, and the unique epigenetic signatures associated with various cancers, such as brain tumors or leukemias to detect powerful diagnostic markers or predictors of therapeutic response. The Interview starts with Dr. van Bömmel sharing her work on co-occurring transcription factors within cell-type specific enhancers, describing the pioneering use of DNA sequencing and its substantial implications in understanding chromatin accessibility. We explore the findings that revealed varying transcription factor interactions across cell types, emphasizing the complexity inherent in gene regulation. Although her research largely remained in silico, its findings paved the way for potential validation through advanced sequencing techniques. The discussion broadens to encompass Dr. van Bömmel's work on pediatric acute lymphoblastic leukemia, where she elaborates on the epigenetic dynamics observed in patient samples. We discuss her collaboration on a large project that aimed to elucidate the methylation profiles of leukemia patients and how specific epigenetic modifications might indicate cancer subtypes. As the conversation shifts towards aging, Dr. van Bömmel explains her research on DNA methylation trajectories in mouse models. This work unearthed unexpected patterns of abrupt changes in methylation that correspond to distinct life stages, reflecting the potential applicability of these findings in understanding human aging processes. Delving further into her innovative research, she introduces 'Methylizer,' a groundbreaking DNA methylation-based classifier designed for brain tumor diagnostics. We examine the rapid diagnostic capabilities this tool offers in surgical contexts, illustrating a paradigm shift in how epigenetic data can inform real-time clinical decisions. Now at the LMU in Munich, Dr. van Bömmel shares her experiences establishing her lab and her intent to foster a computational-focused research environment that collaborates closely with wet lab scientists. We discuss her aspirations to integrate various layers of epigenetic data through advanced statistical methods and to investigate the aging dynamics of brain cells, specifically in the context of neurodegenerative diseases like Alzheimer's. References Van Bömmel, A., Love, M. I., Chung, H.-R., & Vingron, M. (2018). coTRaCTE predicts co-occurring transcription factors within cell-type specific enhancers. PLOS Computational Biology, 14(8), e1006372. https://doi.org/10.1371/journal.pcbi.1006372 Olecka, M., van Bömmel, A., Best, L., Haase, M., Foerste, S., Riege, K., Dost, T., Flor, S., Witte, O. W., Franzenburg, S., Groth, M., von Eyss, B., Kaleta, C., Frahm, C., & Hoffmann, S. (2024). Nonlinear DNA methylation trajectories in aging male mice. Nature communications, 15(1), 3074. https://doi.org/10.1038/s41467-024-47316-2 Brändl, B., Steiger, M., Kubelt, C., Rohrandt, C., Zhu, Z., Evers, M., Wang, G., Schuldt, B., Afflerbach, A. K., Wong, D., Lum, A., Halldorsson, S., Djirackor, L., Leske, H., Magadeeva, S., Smičius, R., Quedenau, C., Schmidt, N. O., Schüller, U., Vik-Mo, E. O., … Müller, F. J. (2025). Rapid brain tumor classification from sparse epigenomic data. Nature medicine, 31(3), 840–848. https://doi.org/10.1038/s41591-024-03435-3 Related Episodes Evolutionary Epigenetic Clocks and Epigenetic Inheritance in Plants (Frank Johannes) Epigenetic Clocks and Biomarkers of Ageing (Morgan Levine) Epigenetic Consequences of DNA Methylation in Development (Maxim Greenberg) Contact Epigenetics Podcast on Mastodon Epigenetics Podcast on Bluesky Dr. Stefan Dillinger on LinkedIn Active Motif on LinkedIn Active Motif on Bluesky Email: podcast@activemotif.com

Join primary care faculty Gary Ferenchick, Kate Rowland, Henry Barry and Mark Ebell as they discuss 4 important new studies: the value (?) Of biomarkers in cognitive impairment, toilet training, bleeding risk with apixaban versus rivaroxaban for VTE, and diagnosing volume overload in adults  from the JAMA Rational Clinical Exam series.

In this episode, I sit down with Dr. Katrin Dreissigacker, a plastic surgeon turned longevity architect and founder of Epigenedit, to explore why hyperbaric oxygen therapy may be one of the most overlooked tools in longevity science.We talk about her journey from a small village in East Germany to becoming known as the “Queen of Needles,” how she reversed markers of biological aging, improved her VO2 max in midlife, and why oxygen, mitochondria, skin health, resilience, and reinvention are all deeply connected.Key Topics:* Hyperbaric oxygen therapy and its role in longevity* Innovations in aesthetic medicine and needling techniques* The impact of oxygen saturation on aging and skin health* Biomarkers of aging and how hyperbaric oxygen influences them* The use of peptides and biohacking for healthspan extensionTimestamps:* 00:00 – Reversing Biological Age? The Power of Oxygen* 00:30 – From East Germany to Elite Medicine* 02:30 – Why She Chose Medicine (Unexpected Path)* 02:57 – What Is Aesthetic Medicine (Beyond Vanity)* 05:14 – “Queen of Needles” & Revolutionizing Fillers* 08:46 – First Encounter with Hyperbaric Oxygen Therapy* 11:24 – From Pandemic to Longevity Innovation* 12:43 – Why She Built Her Own HBOT Chamber* 16:22 – Can HBOT Really Improve VO2 Max?* 18:02 – How HBOT Actually Works (Simple Explanation)* 20:11 – Mild vs Medical HBOT: What's the Difference?* 21:23 – What It Improves: Sleep, Recovery & Aging* 24:00 – How Often Should You Do HBOT?* 26:17 – Risks, Side Effects & Common Fears* 30:40 – The Real Benefits (Why You Don't Feel It Immediately)* 33:29 – Skin, Collagen & The ‘Glow Effect'* 36:04 – Who Should NOT Use HBOT?* 38:22 – Peptides: Hype or Breakthrough?* 42:48 – Biggest Misconceptions About HBOT* 44:24 – Most Overused Aesthetic Treatment Today* 47:10 – Daily Habits for Longevity & Energy* 48:08 – What Shows Up on Your Skin the Most?* 49:49 – Reinvent Yourself at Any AgeABOUT DR. KATRIN DREISSIGACKER: Physician, pioneer in aesthetic medicine and Co-Founder of EpigenEdit, believes ageing is not something to fight but something to design. After three decades at the forefront of aesthetics, she now focuses on longevity science, using tools such as mild hyperbaric oxygen therapy to support cellular regeneration, performance, and vitality from within.RESOURCES MENTIONED:* www.epigenedit.com* Instagram: @epigenedit_europe / @katrin_dreissigacker* LinkedIn: www.linkedin.com/in/katrin-dreissigacker* Katrin's individual practice: www.katrin-dreissigacker.comABOUT NINA'S NOTES: Nina's Notes explores the intersection of longevity science, neuroscience, and human optimization. Hosted by Nina Patrick, PhD in pharmaceutical sciences and longevity researcher, each episode translates cutting-edge research into actionable insights for living longer, better.CONNECT WITH NINA'S NOTESNewsletter: www.ninasnotes.xyzLinkedIn: www.linkedin.com/in/ninapatrick/Website: www.ninapatrick.xyzThanks for reading Nina's Notes! This post is public so feel free to share it. Get full access to Nina's Notes at www.ninasnotes.xyz/subscribe

The number one side effect of comfort is chronic disease, and we're more comfortable than any generation in human history. In this episode, Dr. Clay Moss and I unpack the simple, foundational shifts that produced life-changing results in a 7-day in-patient metabolic rehabilitation protocol: full elimination diet, sleep hygiene, intentional movement, stress management, and community connection. No biohacking gadgets required. Just a return to the basics, your biology was built for. CLICK HERE TO BECOME GARY'S VIP!: https://bit.ly/4ai0Xwg Listen to "Off Label with Dr. Clay Moss" on all your favorite platforms! YouTube: https://bit.ly/4defyfj  Spotify: https://bit.ly/4t5CbY7  Connect with Dr. Clay Moss Website: https://bit.ly/4cGbCE7  YouTube: https://bit.ly/423HwEo  Instagram: https://bit.ly/4mZqjoZ  Facebook: https://bit.ly/4teExEk  TikTok: https://bit.ly/423KkkU  X: https://bit.ly/3R88atg  LinkedIn: https://bit.ly/4cVVAVx  Thank you to our partners A-GAME: “ULTIMATE15” FOR 15% OFF: http://bit.ly/4kek1ij  AION: “ULTIMATE10” FOR 10% OFF: https://bit.ly/4h6KHAD  AIRES: "ULTIMATE20 " FOR 20% OFF: https://bit.ly/4a3Duze  BAJA GOLD: "ULTIMATE10" FOR 10% OFF: https://bit.ly/3WSBqUa  BODYHEALTH: “ULTIMATE20” FOR 20% OFF: http://bit.ly/4e5IjsV  COLD LIFE: THE ULTIMATE HUMAN PLUNGE: https://bit.ly/4eULUKp  CYMBIOTIKA: "ULTIMATE10" FOR 10% OFF: https://bit.ly/4tjyluP  GENETIC METHYLATION TEST (UK ONLY): https://bit.ly/48QJJrk  GENETIC TEST (USA ONLY): ⁠https://bit.ly/3Yg1Uk9  GOPUFF: GET YOUR FAVORITE SNACK!: https://bit.ly/4obIFDC   H2TABS: “ULTIMATE10” FOR 10% OFF: https://bit.ly/4hMNdgg  HEALF: 10% OFF YOUR ORDER: https://bit.ly/41HJg6S  PEPTUAL: “TUH10” FOR 10% OFF: https://bit.ly/4mKxgcn  SNOOZE: LET'S GET TO SLEEP!: https://bit.ly/4pt1T6V  WHOOP: JOIN & GET 1 FREE MONTH!: https://bit.ly/3VQ0nzW  Watch  the “Ultimate Human Podcast” every Tuesday & Thursday at 9AM EST: YouTube: https://bit.ly/3RPQYX8 Podcasts: https://bit.ly/3RQftU0 Connect with Gary Brecka Instagram: https://bit.ly/3RPpnFs TikTok: https://bit.ly/4coJ8fo X: https://bit.ly/3Opc8tf Facebook: https://bit.ly/464VA1H LinkedIn: https://bit.ly/4hH7Ri2 Website: https://bit.ly/4eLDbdU Merch: https://bit.ly/4aBpOM1 Newsletter: https://bit.ly/47ejrws Ask Gary: https://bit.ly/3PEAJuG Timestamps 00:00 ​Intro of Show 04:18 Metabolic Syndrome Definition 06:00 Dr. Clay Moss's Medical Journey 16:05 Biomarkers to Start 23:14 Functional Medicine Program 28:25 Stress Management Protocols 21:35 GLP-1: Pros and Cons 37:21 Future of Peptides 41:42 When Should People Take Peptides, GLP-1? 47:54 Muscle as Our Metabolic Currency 53:14 Female Hormone Therapy Benefits 58:04 Dr. Clay Moss's Mission-Vision 1:03:38 How to Improve Sleep Hygiene 1:08:08 Connect with Dr. Moss 1:08:40 What does it mean to you to be an Ultimate Human? Disclaimer: This podcast is for informational purposes only and does not provide medical advice. It is not intended for diagnosing or treating any health condition. Always consult a licensed healthcare professional before making health or wellness decisions. Gary Brecka is the owner of Ultimate Human, LLC which operates The Ultimate Human podcast and promotes certain third-party products used by Gary Brecka in his personal health and wellness protocols and daily life and for which Ultimate Human LLC and / or Gary Brecka directly or indirectly holds an economic interest or receives compensation.  Accordingly, statements made by Gary Brecka and others (including on The Ultimate Human podcast) may be considered.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Are biomarkers the missing link in personalized prostate cancer care? What is the practical role of biomarkers across the prostate cancer treatment continuum? In this episode of BackTable Urology, Dr. Udit Singhal (University of Michigan) joins Dr. Ruchika Talwar (Vanderbilt University) to explore the evolving role of genomic classifiers and biomarkers in prostate cancer care. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported byVeracytehttps://www.veracyte.com/decipher-prostate --- Timestamps 00:00 - Introduction04:58 - Current State10:07 - Interpreting High Risk Scores13:25 - Intermediate Risk Decisions16:18 - Imaging vs. Genomics18:26 - Advanced Disease Evidence22:02 - AI and Clinical Trials29:52 - Conclusions --- More about this episode They review commonly used assays, including Prolaris, Oncotype Dx, Decipher, and ConfirmMDx and emphasize how these tools complement traditional clinical and pathologic risk factors. The discussion highlights practical applications across the disease continuum from initial diagnosis and active surveillance to intermediate-risk management and post-prostatectomy salvage decisions. They also explore emerging AI-driven tools and ongoing trials, highlighting the importance of contextualizing biomarker data within the broader clinical picture and using it to inform, rather than dictate, patient-centered care. --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

In this episode of the WCNFluencer podcast, host Christopher MacLellan interviews Dr. Mark Goldstein, a founding member of GEM Research. Throughout the episode, Christopher and Dr. Goldstein discuss Dr. Goldstein's transition from private practice to a focus on clinical trials, particularly in Alzheimer's. The conversation covers the importance of clinical trials, the distinction between Alzheimer's and dementia, recognizing symptoms, current treatments, hereditary factors, and the broader research focus at JEM Research Institute. Dr. Goldstein emphasizes the need for early intervention and the potential for future breakthroughs in Alzheimer's treatment. Takeaways - Dr. Goldstein transitioned from private practice to clinical trials. - Clinical trials are essential for developing new medications. - Dementia is a broader term, with Alzheimer's being a major type. - Recognizing early symptoms is crucial for caregivers. - Biomarkers can help diagnose Alzheimer's earlier than before. - Current treatments slow progression but are not cures. - Hereditary factors can increase the risk of Alzheimer's. - GEM Research conducts trials for various neurological conditions. - Combination therapies may be the future of Alzheimer's treatment. - Participation in clinical trials is free and private. To learn more about Dr. Goldstein and JEM Research Institute, click HERE!

In this episode of the WHOOP Podcast How To Series, WHOOP Global Head of Human Performance and Principal Scientist, Dr. Kristen Holmes, sits down with renowned longevity expert, Dr. Darshan Shah, to break down how to maximize longevity. The episode focuses on what truly drives healthspan, drawing from Dr. Shah's own experience as a trauma surgeon. Dr. Shah explains why most chronic diseases are preventable and reversible and why lasting change comes from mastering the fundamentals: sleep quality, daily movement, nutrition, stress management, and consistent data tracking. The conversation explores key biomarkers, the dangers of sedentary living, the role of toxins and environment, and the importance of habit formation, purpose, and emotional health. Together, Dr. Shah and Dr. Holmes reframe longevity not as living longer, but as living better— extending vitality, resilience, and performance throughout life.(00:47) Intro to Dr. Darshan Shah, Longevity Expert(01:14) How Chronic Illness Impacted Dr. Shah Firsthand(06:15) Dr. Shah: From Trauma Surgeon to Longevity Focused Lifestyle(09:30) Building Next Health: Dr. Shah's Impact on the Longevity World(13:10) Biggest Barrier For Patients: What Trends Dr. Shah Is Seeing (19:50) The Influence of a Morning Routine on Health and Longevity(21:36) Looking At The Biggest Game Changer: Movement Throughout The Day(24:26) Eliminating The “All or Nothing” Mentality(28:23) Beyond Sedentary Behavior: Habits Declining Longevity(37:18) Best Biomarkers Promoting Longevity(48:04) Optimization Beyond Nutrition, Sleep, and Exercise (Advanced Advice)(52:28) Combatting Trauma and Understanding The Nervous System(56:18) Dr. Shah's Wellness Wheel: 12 Aspects of Health(58:52) Technological Development In Health and Longevity(59:43) Menopause and Longevity: How Women Can Mitigate Symptoms(01:08:18) Policy Changes That Will Aid Health and LongevityFollow Dr. Darshan ShahInstagram WebsiteDr. Shah's Guide to Minimizing Toxic ExposureDr. Shah's Guide to Biomarkers  Support the showFollow WHOOP:Sign up for WHOOP Advanced LabsTrial WHOOP for Freewww.whoop.comInstagramTikTokYouTubeXFacebookLinkedInFollow Will Ahmed:InstagramXLinkedInFollow Kristen Holmes:InstagramLinkedInFollow Emily Capodilupo:LinkedIn 

The "Community Meets Clinic" podcast series introduces clinicians and healthcare personnel specializing in rare neuroimmune disorders. In this episode hosted by Krissy Dilger of SRNA, we met Dr. Grace Gombolay and Dr. Varun Kannan, both from Emory University and Children's Healthcare of Atlanta, designated Centers of Excellence in Rare Neuroimmune Disorders. Dr. Kannan discussed learning alongside families as conditions like MOG antibody disease emerged clinically and his focus on tailoring treatment and supporting clinical trials in a field with few approved therapies [03:37]. Dr. Gombolay outlined her research on biomarker development, a Children's biobank, advanced MRI collaborations, and participation in the Network of Pediatric MS Centers covering disorders such as MOGAD, NMOSD, optic neuritis, ADEM, and TM [06:36]. They described their multidisciplinary clinic team, highlighted home infusions and telemedicine to reduce burden, and shared personal self-care strategies [10:22]. Dr. Gombolay and Dr. Kannan expressed hope for more trials, remyelination, prevention, and earlier diagnosis aided by AI prompts [20:43].You can view Dr. Grace Gombolay's medical profile here:https://www.choa.org/doctors/grace-gombolayYou can view Dr. Varun Kannan's medical profile here:https://www.choa.org/doctors/varun-kannanGrace Gombolay, MD, MSc, FAAN is an Associate Professor at Emory University and Director of the Pediatric Neuroimmunology and Multiple Sclerosis Clinic at Children's Healthcare of Atlanta. Her research interest involves biomarker development in pediatric neuroinflammatory diseases including autoimmune encephalitis, multiple sclerosis, MOGAD, and NMOSD.Varun Kannan, MD graduated from Emory University School of Medicine in 2017. He then completed child neurology residency in 2022, followed by pediatric neuroimmunology and multiple sclerosis fellowship at Baylor College of Medicine and Texas Children's Hospital in 2023. He returned to Emory and Children's Healthcare of Atlanta in 2023, where he has worked closely with Dr. Grace Gombolay in the neuroimmunology program. He is interested in clinical research regarding severe/relapsing forms of rare neuroimmune disorders including autoimmune encephalitis and MOGAD. He is currently involved in multiple upcoming phase 3 clinical trials exploring new disease modifying treatments for pediatric rare neuroimmune disorders. He is also passionate about medical education and is currently one of the Associate Program Directors for the Emory child neurology residency.00:00 Welcome01:56 Dr. Grace Gombolay's Journey03:37 Dr. Varun Kannan's Path05:06 Kannan's Research Focus06:36 Biomarkers and Biobank10:22 Clinic Team and Care13:44 Self Care and Balance16:15 Children's Healthcare of Atlanta20:43 Hopeful Future Ahead24:49 Closing

“The awareness of how lifestyle, diet, and exercise affect us is mind-blowing.” Dr. Giovanni Campanile and Dr. Sandra Cammarata are the founders of CorAeon, the only functional medicine practice founded and led by a husband-and-wife team. Campanile is a Harvard-trained functional cardiologist, Associate Professor of Medicine at Rutgers, New Jersey Medical School, and former cardiologist for the President of the United States, George H.W. Bush. Cammarata is a Tufts-trained functional psychiatrist with 36 years of experience and multiple Castle Connolly Top Doctor honors. Together, they treat cardiovascular health and mental well-being as one inseparable system. They are co-authors of The Sicilian Secret Diet Plan and hosts of the podcast The Rest is Health. 00:00 - The mind-body approach to heart health 03:01 - How relationships predict lifespan 05:18 - The Monday morning heart attack 09:13 - Where healthy people get tripped up 13:02 - Visceral fat & body composition testing 15:28 - Biomarkers beyond cholesterol 23:25 - The problem with a zero CAC score 25:09 - Medications for heart disease risk 28:22 - When stress is the real driver 31:46 - EXO Mind & magnetic brain stimulation 35:34 - The problems with traditional cardiology 41:00 - The benefits of sauna therapy 44:46 - The hidden epidemic: insulin resistance 47:57 - The future of heart health Referenced in the episode:  Harvard longevity study: https://www.adultdevelopmentstudy.org/  This podcast is sponsored by CorAeon, the only functional medicine practice created by a functional cardiologist and functional psychiatrist team for a true mind-body approach. Learn more at coraeon.com.  We hope you enjoy this episode, and feel free to watch the full video on YouTube! Whether it's an article or podcast, we want to know what we can do to help here at mindbodygreen. Let us know at: podcast@mindbodygreen.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

Can identifying the right patients and the right endpoints transform how we test new osteoarthritis treatments? On this week's episode of Joint Action, we unpack what the FNIH Biomarkers Consortium has learned so far, and how their latest phase aims to deliver biomarkers that can make disease-modifying OA drug trials smaller, faster, and more likely to succeed.Dr. Virginia Byers Kraus is a Professor of Medicine, Pathology, and Orthopaedic Surgery at Duke University School of Medicine. A rheumatologist and translational scientist, her research focuses on osteoarthritis and biomarker development as part of the international FNIH Biomarkers Consortium.Peter G. Mesenbrink, Ph.D., is Executive Director of Biostatistics at Novartis and industry co-chair of the FNIH Biomarkers Consortium. With expertise in adaptive trial design, surrogate endpoint development, and data sharing policy, he is a frequent collaborator across industry, regulatory, and academic communities.Dr. Jamie Collins is a biostatistician at Brigham and Women's Hospital and Associate Professor of Orthopaedic Surgery at Harvard Medical School. As lead statistician for the FNIH OA Biomarkers Consortium, her research focuses on strengthening osteoarthritis clinical trials through innovative trial design and prognostic enrichment.RESOURCESFNIH: Treatment Response Biomarkers for Disease Modifying Osteoarthritis Drugs (DMOADs)CONNECT WITH USNaia Health: https://www.naiahealth.com.au/st-leonards-hubJoin one of our trials https://www.osteoarthritisresearch.com.au/current-trialsInstagram: @ProfDavidHunterTwitter: @ProfDavidHunter @jointactionorgEmail: hello@jointaction.infoWebsite: www.jointaction.info/podcastIf you enjoyed this episode, don't forget to subscribe to learn more about osteoarthritis from the world's leading experts! And please let us know what you thought by leaving us a review! Hosted on Acast. See acast.com/privacy for more information.

In this podcast, experts Adam Brufsky, MD, PhD; Kamel Abou Hussein, MD; and Priyanka Sharma, MD, FASCO, discuss personalizing care in early-stage triple-negative breast cancer (TNBC) and the evolving first-line strategies and their implications for downstream sequencing in metastatic TNBC.

Full Show Notes: https://bengreenfieldlife.com/trupodcast In this episode with repeat guest Dr. Matt Dawson, you’ll discover how epigenetic testing analyzes DNA methylation to reveal how fast you’re biologically aging, what’s driving your health, and your risk for disease. You’ll explore how these signals can detect chronic disease risk earlier than traditional labs, and how TruDiagnostic built the TruHealth Test by analyzing ~1,000 biomarkers to pinpoint the most meaningful health indicators. We also break down the TruAge Test, covering biological age, pace of aging, and organ-specific aging, plus insights from my own results. We discuss how AI and large language models (LLMs) identify which interventions actually improve specific biomarkers, and what truly moves the needle for longevity, from caloric restriction and GLP-1 drugs to the often-overlooked impact of relationships, stress, and recovery.

In this episode of the WHOOP Podcast, WHOOP Founder and CEO Will Ahmed sits down with Quest Diagnostics CEO Jim Davis to discuss the partnership behind WHOOP Advanced Labs. Will and Jim discuss how combining blood biomarkers with continuous physiological data is reshaping consumer health. Will and Jim explore how trends in metrics like cholesterol, glucose, sleep, and recovery can drive more personalized, actionable insights and help shift healthcare from reactive to preventative. Jim shares his personal approach to health tracking, Quest's vision for democratizing lab testing, and leadership lessons from running a 50,000+ employee organization. Jim gets candid about his “obsession” with his WHOOP data and his advice for managing stress and staying focused on long-term health habits.Sign up for WHOOP Advanced Labs, available now in the WHOOP app. Learn more about WHOOP Advanced Labs here.(01:12) Jim Davis on the WHOOP x Quest Diagnostics Partnership(03:06) What WHOOP Members Can Expect From WHOOP Advanced Labs(07:10) Action From Insight: Understanding Trends To Optimize Your Health(12:27) How Frequently Should You Check Your Biomarkers? (13:25) Building The Tech: The Challenges of Health Innovation(18:10) Establishing Wellness Trends: Why Annual Bloodwork Matters(20:41) Lifestyle Factors That Can Cause Issues In Health & Biomarkers(22:23) Growing The Business: Jim's Vision For The Future of Quest(30:25) Do We Need Supplements?: What Your Bloodwork Says About Supplementation(32:37) Jim Davis on Understanding Blood Biomarkers & Using WHOOP To Form Healthy Habits(37:00) Jim's Lessons on Operational ExcellenceSupport the showFollow WHOOP:Sign up for WHOOP Advanced LabsTrial WHOOP for Freewww.whoop.comInstagramTikTokYouTubeXFacebookLinkedInFollow Will Ahmed:InstagramXLinkedInFollow Kristen Holmes:InstagramLinkedInFollow Emily Capodilupo:LinkedIn 

Biomarkers are playing an increasingly critical role in shaping the future of oncology trials—and the pace of innovation is accelerating. In this sponsored episode of The Top Line, host Stephanie Butler sits down with Dr. Danielly Vicente, Associate Medical Director of Oncology and Hematology at Allucent, to explore how advanced biomarker strategies are transforming clinical development. From improving patient selection in early-phase trials to enabling adaptive study designs, biomarkers are helping researchers identify the right patients, optimize outcomes, and reduce development risks. Dr. Vicente discusses how approaches like comprehensive genomic profiling, basket and umbrella trials, and real-time monitoring are driving more efficient and successful oncology programs. The episode also tackles the challenges of integrating genomic testing and biomarker screening into trials, including operational complexity and data coordination. Plus, learn how emerging technologies such as circulating tumor DNA (ctDNA) and multiomic strategies are set to redefine trial design and accelerate precision medicine. Tune in to hear how biomarker-driven innovation is advancing oncology research—and what it means for the future of patient care.See omnystudio.com/listener for privacy information.

Interview with Susan M. Landau, PhD, author of Brain Imaging Biomarkers and Cognitive Outcomes in a Multidomain Lifestyle Intervention: The POINTER Imaging Ancillary Study. Hosted by Cynthia E. Armand, MD. Related Content: Brain Imaging Biomarkers and Cognitive Outcomes in a Multidomain Lifestyle Intervention

In this episode, we explore a groundbreaking development in the diagnosis of chronic fatigue syndrome (CFS/ME) — a condition that affects millions worldwide, yet remains notoriously difficult to identify… Joining the podcast to discuss this topic are Alexandre Akoulitchev and Dmitry Pshezhetskiy, who break down a novel blood test designed to detect biological signatures associated with chronic fatigue. Their work centers on cutting-edge epigenetic science and biomarker discovery, offering new possibilities for more objective and earlier diagnosis of complex, hard-to-measure conditions. Hit play to discover: How a blood-based biomarker test may help identify chronic fatigue syndrome. The role of epigenetics in understanding complex, "invisible" illnesses. The four key symptoms of ME/CFS, and why it's so difficult to diagnose. How inflammation signals can contribute to chronic fatigue. Alexandre Akoulitchev is a molecular biologist specializing in genome regulation and chromatin architecture. He is a cofounder of Oxford BioDynamics and the creator of its EpiSwitch biomarker platform. He earned his PhD in cell biology from University College London. Dmitry Pshezhetskiy is a Professorial Research Fellow at Norwich Medical School and an academic clinician focused on cancer biology and therapeutic research. He completed his academic training at Moscow State University, Montréal institutions, and leading research centers in France, building a strong background in molecular medicine and translational research. You can connect with Alexandre Akoulitchev here and Dmitry Pshezhetskiy here!

What made this time different after years of losing and regaining weight? Episode #251